Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A (Vibostolimab/Pembrolizumab) Basket Study in Advanced Solid Tumors
NCT05007106Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of vibostolimab in Cervical Cancer (CC), endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC), cholangiocarcinoma (CCA), esophageal cancer, sponsored by Merck & Co.. Started Sep 2021; status: completed.
02
Drugs
vibostolimab
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)cholangiocarcinoma (CCA)esophageal cancer
Beyond the preview
Go deeper on NCT05007106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007106.